This trial is looking for genetic variants associated with the effects of a GLP1R agonist on insulin secretion and glucose metabolism in overweight/obese, otherwise healthy Amish volunteers.
3 Primary · 1 Secondary · Reporting Duration: Assessed after completing 6 weeks of semaglutide therapy
600 Total Participants · 1 Treatment Group
Primary Treatment: Semaglutide Pen Injector [Ozempic] · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 89 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|Amish Research Clinic||100.0%|
|Did not meet criteria||50.0%|